Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Rahul Aggarwal
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04926181CT.gov Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Small Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cetrelimab (this asset) | Rahul Aggarwal | P2 | CCC · 53 |
| Nogitecan | National Cancer Institute (NCI) | P2 | BB |
| Etoposide | SystImmune Inc. | P3 | BB |
| Vinorelbine Ditartrate | EpicentRx, Inc. | P2 | BB |
| Lurbinectedin | SystImmune Inc. | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | EpicentRx, Inc. | P2 | BB |
| Pembrolizumab | Thomas Jefferson University | P2 | BB |
| Carboplatin | SystImmune Inc. | P3 | BB |
| Berzosertib | National Cancer Institute (NCI) | P2 | BB |
+22 more in the Small Cell Carcinoma cohort
Other indications for Cetrelimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Cancer | — | P2 | B · 60 |
| Castration-Resistant Prostate Carcinoma | — | P2 | CCC · 55 |
| Metastatic Prostate Carcinoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cetrelimab in Small Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cetrelimab-small-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →